WuXi AppTec, the Shanghai-based biotech giant, has sold its South Philly-based WuXi Advanced Therapies contract manufacturing unit to New York-based Altaris LLC, easing worries that federal limits ...

NAMSA recently announced plans to acquire WuXi AppTec’s medical device testing operations in the U.S. As part of the ...

The companies have committed to working in close collaboration to ensure a smooth transition for employees and customers.

WuXi AppTec is parting ways with its U.S. medical device testing business, selling its two stateside locations to the Ohio-based regulatory consulting firm NAMSA. The deal includes facilities in ...

WuXi AppTec had said in December its units had signed a deal with U.S.-based private equity firm Altaris LLC for the sale of the U.S. and UK-based operations of its cell and gene therapy unit.

Pharmaron, a Chinese biotech firm, is currently using hundreds of thousands of taxpayer dollars to test pharmaceuticals on up ...

WuXi AppTec Co. and WuXi Biologics Cayman Inc. said they see a brighter 2025 for the Chinese biotech and drug companies after the US Biosecure legislation that threatened to cut them out from ...

SHANGHAI, Jan. 13, 2025 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life sciences ...

Wuxi city captivated hundreds of millions of viewers across China and around the world at the 2025 CMG Spring Festival Gala ...

Catch up on January’s top pharma news, from major industry deals and cutting-edge medical innovations to advancements in ...